|
Market Closed -
NYSE
21:02:42 09/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 99.60 USD | +1.13% |
|
+2.15% | -20.50% |
| 10-09 | Trump Disclosed 517 Securities Transactions in August, Including Up to $25 Million Meta Purchase | MT |
| 10-07 | Abbott Introduces Ensure Max Protein 3-In-1 Muscle Support Protein Powder | CI |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 172,346 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -20.89% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 196,285 | 193,303 | 189,613 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -11.69% | -1.52% | -1.91% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 29.2x | 22.6x | 19.8x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.6x | 3.45x | 3.27x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -3.57x | 0.8x | 1.4x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.43x | 3.16x | 2.96x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.91x | 3.54x | 3.25x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.1x | 13.4x | 11.9x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 16.7x | 14.8x | 13.2x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 26x | 21.7x | 19.8x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.84% | 4.62% | 5.06% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.57 | 2.741 | 2.898 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.58% | 2.75% | 2.91% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.416 | 4.402 | 5.024 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 75.2% | 62.3% | 57.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,203 | 54,532 | 58,260 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,982 | 14,468 | 15,892 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,720 | 13,022 | 14,320 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,212 | 7,894 | 8,780 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 99.60 | 99.60 | 99.60 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 29.16x | 3.91x | 15.12x | 2.58% | 172B | |
| 18.92x | 3.45x | 12.33x | 3.18% | 113B | |
| 21.59x | 4.24x | 14.82x | 1.3% | 106B | |
| 25.92x | 2.55x | 10.24x | 2.77% | 75.31B | |
| 17.73x | 0.21x | 12.94x | 0.73% | 61.8B | |
| 30.68x | 7.58x | 19.64x | 1.3% | 52.93B | |
| 35.41x | 3.42x | 11.72x | 2.14% | 50.05B | |
| 35.08x | 8.72x | 24.53x | -.--% | 40.81B | |
| 33.8x | 5.92x | 18.59x | -.--% | 31.74B | |
| 48.93x | 1.34x | 12.38x | 0.2% | 31.81B | |
| Average | 29.72x | 4.13x | 15.23x | 1.42% | 73.64B | |
| Weighted average by Cap. | 27.12x | 3.91x | 14.61x | 1.87% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
